<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00217295</url>
  </required_header>
  <id_info>
    <org_study_id>MSI-101</org_study_id>
    <secondary_id>BiogenIdec</secondary_id>
    <secondary_id>Ortho-McNeil</secondary_id>
    <nct_id>NCT00217295</nct_id>
  </id_info>
  <brief_title>A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis</brief_title>
  <official_title>A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Multiple Sclerosis Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Multiple Sclerosis Institute</source>
  <brief_summary>
    <textblock>
      This is a clinical trial in relapsing-remitting Multiple Sclerosis to determine if Topamax
      added to Avonex has a neuroprotective effect as measured by the brain parenchymal fraction (
      a measure of brain shrinkage) and by clinical assessment scores to evaluate disease
      progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol requires all participants to be treated with Avonex and in addition patients
      will be blindly assigned to either a group who receive Topamax or a placebo control. Repeated
      neurological and clinical examinations are performed with laboratory tests to determine any
      possible adverse drug effects. The scaled neurologic examinations (EDSS and MSFC) and brain
      MRI's are done at regular intervals to evaluate possible treatment effects.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2004</start_date>
  <completion_date>December 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain atrophy on nMRI</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression on EDSS and MSFC</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avonex and Topamax</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Relapsing-remitting multiple sclerosis

        Exclusion Criteria:

        Secondary progressive multiple sclerosis Contraindication to MRI Systemic disease Pregnancy
        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey I Greenstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MSI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey I Greenstein, MD</last_name>
    <phone>215-985-2245</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Multiple Sclerosis Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey I Greenstein, MD</last_name>
      <phone>215-985-2245</phone>
    </contact>
    <contact_backup>
      <last_name>Iris J Gold, MBA</last_name>
      <phone>215-985-2245</phone>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey I Greenstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>September 14, 2005</last_update_submitted>
  <last_update_submitted_qc>September 14, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2005</last_update_posted>
  <keyword>Relapsing-remitting multiple sclerosis</keyword>
  <keyword>Brain atrophy</keyword>
  <keyword>Disease progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferon beta-1a</mesh_term>
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

